<DOC>
	<DOCNO>NCT02912936</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics/dynamics ketogenic dietary supplement contain medium chain triglyceride ( MCTs ) patient Alzheimer disease ( AD ) . Novel image laboratory biomarkers response intervention also explore .</brief_summary>
	<brief_title>A Medium Chain Triglyceride Intervention Patients With Alzheimer Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis mildmoderate Alzheimer disease ( AD ) MiniMental State Examination ( MMSE ) 1626 Study partner available frequent contact participant Good visual auditory acuity neuropsychological test Education include completion least six grade Must read speak English fluently Antidepressants permit , stable 4 week prior screen ( participant currently depress history major depression within past 1 year ) Cholinesterase inhibitor permit , stable 12 week prior screen Any significant neurologic disease AD History Diabetes Mellitus type I II Any contraindication MRI PET study Major depression , bipolar disorder describe within past 1 year . History schizophrenia History alcohol substance abuse dependence within past 2 year Any significant systemic illness unstable medical condition , could lead difficulty comply protocol Current use specific psychoactive medication Investigational amyloid lower therapy prohibit two month prior screen duration trial . Other investigational agent prohibit one month prior screen duration trial . Cancer last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>medium chain triglyceride</keyword>
	<keyword>MCT</keyword>
	<keyword>coconut oil</keyword>
	<keyword>MRI</keyword>
	<keyword>PET</keyword>
	<keyword>ketone</keyword>
</DOC>